Canada markets close in 56 minutes

Pharmadrug Inc. (LMLLF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0180-0.0061 (-25.23%)
As of 12:53PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close0.0241
Open0.0214
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0148 - 0.0214
52 Week Range0.0148 - 0.0575
Volume270,200
Avg. Volume38,642
Market Cap1.694M
Beta (5Y Monthly)2.91
PE Ratio (TTM)0.90
EPS (TTM)0.0200
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    PharmaDrug's SecureDose Announces the Advancement of Process Development of Its Biosynthetic Formulation of Pharmaceutical Grade Cocaine

    Victoria's Chiral Labs to lead development of novel cocaine manufacturing process Toronto, Ontario--(Newsfile Corp. - April 16, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances, natural medicines, and previously approved drugs, is pleased to announce that the Company's wholly-owned subsidiary, Securedose Synthetics Inc. ("SecureDose") has en

  • Newsfile

    PharmaDrug's SecureDose Announces Filing of US Provisional Patent for Manufacturing Method for Biosynthetic Pharmaceutical Grade Cocaine

    Toronto, Ontario--(Newsfile Corp. - March 13, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC PINK: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances, natural medicines, and previously approved drugs, is pleased to announce that it has initiated work on a project to develop a novel manufacturing method for the commercial-scale manufacture of cocaine to support safe supply programs. PharmaDrug ha

  • Newsfile

    PharmaDrug Appoints Current Board Member Dr. David Kideckel as Chairman

    Toronto, Ontario--(Newsfile Corp. - February 27, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is pleased to announce that current board member Dr. David Kideckel has been appointed Chairman of the Board of PharmaDrug replacing Robert Steen who will remain as CEO of